Physician profile
Maged Boutros
NPI 1497785281
$12,382.44
in general payments reported to CMS, 2019-2025
43 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $995 · 2021: $1,384 · 2022: $1,806 · 2023: $2,695 · 2024: $2,389 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,405 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,405.18 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,851.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,489.50 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,273.42 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Astrazeneca Pharmaceuticals LP | $1,219.43 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,144.82 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $817.99 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $802.90 | 2021-2025 | Vraylar, Linzess, Creon |
| Amarin Pharma, INC. | $548.49 | 2019-2023 | |
| Astellas Pharma US INC | $345.36 | 2023-2025 | Veozah |
| Edwards Lifesciences Corporation | $318.84 | 2022-2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.76 | 2021-2025 | Jardiance |
| Abbott Laboratories | $299.25 | 2022-2023 | Pressurewire |
| Exact Sciences Corporation | $216.22 | 2023-2025 | Cologuard Collection Kit |
| Vivus LLC | $205.48 | 2019-2024 | Qsymia, Pancreaze |
| Kowa Pharmaceuticals America, INC. | $175.84 | 2024-2025 | Zoryve |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $164.98 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $147.56 | 2020-2025 | Contrave, Nexletol |
| Abiomed | $112.61 | 2025 | |
| Pfizer INC. | $97.18 | 2020-2025 | |
| Integra Lifesciences Corporation | $92.73 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Jazz Pharmaceuticals INC. | $81.76 | 2021-2022 | |
| Axsome Therapeutics, INC. | $79.31 | 2023-2025 | Sunosi, Symbravo |
| Aimmune Therapeutics, INC. | $55.37 | 2025 | Zenpep |
| Horizon Therapeutics Plc | $52.70 | 2020-2021 | |
| Antares Pharma, INC. | $46.93 | 2022-2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $41.15 | 2023 | Keveyis |
| Genentech USA, INC. | $40.84 | 2021 | |
| Ardelyx, INC. | $36.26 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $31.33 | 2022-2023 | Strensiq |
| Eisai INC. | $30.25 | 2024 | |
| Nestle Healthcare Nutrition INC. | $29.13 | 2021-2022 | |
| Phadia US INC. | $28.73 | 2021-2024 | Immunocap |
| Nalpropion Pharmaceuticals LLC | $25.00 | 2019 | |
| Linus Health, INC. | $24.23 | 2023 | |
| Dexcom, INC. | $22.48 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $18.95 | 2025 | Korlym |
| Janssen Biotech, INC. | $17.93 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $14.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2024 | Trintellix |
| Lexicon Pharmaceuticals, INC. | $14.80 | 2023 | Inpefa |
| Dermira, INC. | $12.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.